CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
9.39
+0.06 (0.64%)
Sep 28, 2026, 4:08 PM HKT

CSPC Pharmaceutical Group Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
7,4283,8824,3285,8736,0915,605
Depreciation & Amortization
1,2921,3201,2491,0831,004862.38
Other Amortization
92.2792.2790.6534.9443.453.1
Loss (Gain) From Sale of Assets
16.4716.4723.422.237.3610.79
Asset Writedown & Restructuring Costs
--0.1842.3272.1150
Loss (Gain) From Sale of Investments
-286.29-286.29151.94177.85-148.97-242.41
Loss (Gain) on Equity Investments
52.4552.4589.4754.215.4-22.44
Stock-Based Compensation
-65.95-65.95210.45235.09160.7317.73
Provision & Write-off of Bad Debts
-9.97-9.9716.318.41-25.734.07
Other Operating Activities
3,877-308-807.3-330.26-391.27-263.85
Change in Accounts Receivable
391.78391.78692.25-1,973-566.55-943.55
Change in Inventory
42.0342.038.65-583.75-42.75-617.07
Change in Accounts Payable
654.76654.76-758.87918.1318.45276.79
Change in Unearned Revenue
1,3661,366135.12-275.07468.63-44.22
Change in Other Net Operating Assets
-1,317-1,317-894.41-1,118920.34-59.87
Operating Cash Flow
13,5345,8324,5354,1797,6274,637
Operating Cash Flow Growth
114.94%28.60%8.52%-45.21%64.50%-31.20%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,521-1,959-2,015-1,624-2,220-1,410
Sale of Property, Plant & Equipment
47.130.1699.92139.9916.8385.69
Cash Acquisitions
40.47----341.91-24.35
Divestitures
-----150.91
Sale (Purchase) of Intangibles
-386.36-320.25-560.08-265.43-484.54-339.15
Investment in Securities
-6,725-2,080-1,6152,171-4,075630.71
Other Investing Activities
208.93481.75232.62443.5308.74269.01
Investing Cash Flow
-8,337-3,878-3,858865.86-6,796-637.33

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-2128-485.71-
Total Debt Issued
274.412128-485.71-
Long-Term Debt Repaid
--166.88-152.36-166.43-620.95-222.17
Lease Payments
-131.78-138.88-143.41-138.59-125.24-123.17
Total Debt Repaid
-180.78-166.88-152.36-166.43-620.95-222.17
Net Debt Issued (Repaid)
93.63-145.88-124.36-166.43-135.24-222.17
Issuance of Common Stock
20.1522.88106.43---
Repurchase of Common Stock
-420.51-418.45-2,196-458.95-14.21-263.51
Common Dividends Paid
-2,497-2,497-3,234-2,726-2,097-1,691
Other Financing Activities
520.8427.11194792.06342.34-20.16
Financing Cash Flow
-2,283-2,612-5,253-2,560-1,904-2,197

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-10.79-4.813.44.8914.14-2.44
Net Cash Flow
2,903-662.88-4,5732,490-1,0591,800

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
12,0123,8722,5192,5555,4073,226
Free Cash Flow Growth
222.27%53.70%-1.40%-52.74%67.58%-40.07%
Free Cash Flow Margin
38.34%14.89%8.69%8.12%17.48%11.58%
Free Cash Flow Per Share
1.050.340.210.210.450.27
Levered Free Cash Flow
9,8972,9262,1301,1643,8261,721
Unlevered Free Cash Flow
9,9162,9512,1581,1803,8411,726
Free Cash Flow After Leases
11,8813,7332,3762,4175,2823,103

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
11.8410.977.6515.9921.547.66
Cash Income Tax Paid
824.44824.441,6931,3091,3351,141
Change in Working Capital
1,1381,138-817.26-3,032798.12-1,388